FDA accepts applications for Circassia COPD products Duaklir, Tudorza

By Jaime De Leon | Aug 17, 2018 | 3:32 AM GMT

Circassia Pharmaceuticals plc (LSE:CIR) said FDA accepted for review an NDA for Duaklir Pressair aclidinium

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE